27294781|t|N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A
27294781|a|Botulinum neurotoxin serotype A1 (BoNT/A1), a licensed drug widely used for medical and cosmetic applications, exerts its action by invading motoneurons. Here we report a 2.0-Ã…-resolution crystal structure of the BoNT/A1 receptor - binding domain in complex with its neuronal receptor, glycosylated human SV2C. We found that the neuronal tropism of BoNT/A1 requires recognition of both the peptide moiety and an N-linked glycan on SV2. This N-glycan -which is conserved in all SV2 isoforms across vertebrates -is essential for BoNT/A1 binding to neurons and for its potent neurotoxicity. The glycan - binding interface on SV2 is targeted by a human BoNT/A1 - neutralizing antibody currently licensed as an antibotulism drug. Our studies reveal a new paradigm of host-pathogen interactions, in which pathogens exploit conserved host post-translational modifications, thereby achieving highly specific receptor binding while also tolerating genetic changes across multiple isoforms of receptors.
27294781	0	22	N-linked glycosylation	T038	UMLS:C0376322
27294781	26	29	SV2	T103	UMLS:C3711414
27294781	46	53	binding	T038	UMLS:C0033618
27294781	58	64	uptake	T038	UMLS:C0243144
27294781	68	90	botulinum neurotoxin A	T103	UMLS:C0006050
27294781	91	123	Botulinum neurotoxin serotype A1	T103	UMLS:C0006050
27294781	125	132	BoNT/A1	T103	UMLS:C0006050
27294781	137	145	licensed	T170	UMLS:C0023636
27294781	146	150	drug	T103	UMLS:C1254351
27294781	167	174	medical	T103	UMLS:C0013227
27294781	232	243	motoneurons	T017	UMLS:C0026609
27294781	279	296	crystal structure	T103	UMLS:C0444626
27294781	304	320	BoNT/A1 receptor	T103	UMLS:C0006050
27294781	323	337	binding domain	T082	UMLS:C1514535
27294781	341	348	complex	T103	UMLS:C1704241
27294781	358	375	neuronal receptor	T017	UMLS:C2325760
27294781	377	389	glycosylated	T038	UMLS:C0376322
27294781	390	400	human SV2C	T103	UMLS:C3711414
27294781	440	447	BoNT/A1	T103	UMLS:C0006050
27294781	481	495	peptide moiety	T103	UMLS:C0030956
27294781	503	518	N-linked glycan	T103	UMLS:C0032594
27294781	522	525	SV2	T103	UMLS:C3711414
27294781	532	540	N-glycan	T103	UMLS:C0032594
27294781	568	571	SV2	T103	UMLS:C3711414
27294781	572	580	isoforms	T103	UMLS:C0597298
27294781	588	599	vertebrates	T204	UMLS:C0042567
27294781	618	625	BoNT/A1	T103	UMLS:C0006050
27294781	626	633	binding	T038	UMLS:C0033618
27294781	637	644	neurons	T017	UMLS:C0027882
27294781	664	677	neurotoxicity	T037	UMLS:C0235032
27294781	683	689	glycan	T103	UMLS:C0032594
27294781	692	699	binding	T038	UMLS:C0033618
27294781	713	716	SV2	T103	UMLS:C3711414
27294781	734	739	human	T204	UMLS:C0086418
27294781	740	747	BoNT/A1	T103	UMLS:C0006050
27294781	750	771	neutralizing antibody	T103	UMLS:C0475463
27294781	782	790	licensed	T170	UMLS:C0023636
27294781	797	814	antibotulism drug	T103	UMLS:C1254351
27294781	853	879	host-pathogen interactions	T038	UMLS:C1752856
27294781	923	955	post-translational modifications	T038	UMLS:C0033666
27294781	991	1007	receptor binding	T038	UMLS:C0597358
27294781	1030	1045	genetic changes	T038	UMLS:C1705285
27294781	1062	1070	isoforms	T103	UMLS:C0597298
27294781	1074	1083	receptors	T103	UMLS:C0597357